Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-30T15:10:46.708Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficacy and Safety of Lamotrigine for Adults with Bipolar Disorder in a Private Practice Setting

Published online by Cambridge University Press:  07 November 2014

Lawrence D. Ginsberg
Get access Rights & Permissions [Opens in a new window]

Abstract

Introduction

Lamotrigine is approved by the Food and Drug Administration for maintenance therapy in patients with bipolar I disorder. However, several studies of acute-phase and maintenance treatment support the efficacy of lamotrigine for bipolar I and bipolar II disorders. This chart review was performed to assess the efficacy and safety of lamotrigine in the treatment of bipolar disorder in a private psychiatric practice setting and to investigate differences in response among patients with different diagnostic subtypes of bipolar disorder.

Methods

The charts of 587 adult outpatients with a primary diagnosis of bipolar disorder who received treatment with lamotrigine in a private practice setting between July 1998 and May 2004 were reviewed retrospectively. Treatment response was assessed with the Clinical Global Impression-Improvement scale and was defined as achievement of a score of ≤2.

Results

Three hundred forty-nine patients (59.5%) responded to lamotrigine. Response rates were comparable among patients wit h bipolar I disorder, bipolar II disorder, bipolar disorder not otherwise specified, and among patients with bipolar I disorder who presented with depressive, manic, or mixed episodes. Nonserious rash (12.8%) and headache (2.9%) were the most frequently reported adverse events.

Conclusion

These results suggest that lamotrigine is effective and well-tolerated in the treatment of bipolar disorder across the spectrum of sub-types of the illness.

Type
Original Research
Information
CNS Spectrums , Volume 11 , Issue 5 , May 2006 , pp. 376 - 382
Copyright
Copyright © Cambridge University Press 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Narrow, WE, Rae, DS, Robins, LN, Regier, DA. Revised prevalence estimates of mental disorders in the United States. Using a clinical significance criterion to reconcile 2 surveys' estimates. Arch Gen Psychiatry. 2002;59:115–123.CrossRefGoogle ScholarPubMed
2.Dean, BB, Gerner, D, Gerner, RH. A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in bipolar disorder. Curr Med Res Opin. 2004;20:139–154.Google Scholar
3.Goodwin, FK, Jamison, KR. Manic-Depressive Illness. New York, NY: Oxford University Press; 1990.Google Scholar
4.Yatham, LN. Newer anticonvulsants in the treatment of bipolar disorder. J Clin Psychiatry. 2004;65(suppl 10):28–35.Google Scholar
5.Spina, E, Perugi, G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord. 2004;6:57–75.Google Scholar
6.Bowden, CL, Calabrese, JR, McElroy, SL, et al.A randomized, placebo-controlled 12-month trial of divalproex and lithium treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry. 2000;57:481–489.Google Scholar
7.Weisler, RH, Kalali, AH, Ketter, TA; SPD417 Study Group. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry. 2004;65:478–484.Google Scholar
8.Weisler, RH, Keck, PE Jr, Swann, AC, Cutler, AJ, Ketter, TA, Kalali, AH; SPD417 Study Group. Extended-release carbamazepine for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2005;66:323–330.Google Scholar
9. Depakote [package insert]. North Chicago, Ill: Abbott Laboratories; 2004.Google Scholar
10. Equetro [package insert]. Wayne, Penn: Shire US, Inc; 2004.Google Scholar
11.Harden, CL, Goldstein, MA. Mood disorders in patients with epilepsy: epidemiology and management. CNS Drugs. 2002;16:291–302.Google Scholar
12. Lamictal [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2004.Google Scholar
13.Calabrese, JR, Bowden, CL, Sachs, GS, Ascher, JA, Monaghan, E, Rudd, GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry. 1999;60:79–88.Google Scholar
14.Ichim, L, Berk, M, Brook, S. Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. Ann Clin Psychiatry. 2000;12:5–10.Google Scholar
15.Bowden, CL, Calabrese, JR, Sachs, G, et al.A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60:392–400Google Scholar
16.Calabrese, JR, Bowden, CL, Sachs, G, et al.A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003;64:1013–1024.Google Scholar
17.Goodwin, GM, Bowden, CL, Calabrese, JR, et al.A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar disorder. J Clin Psychiatry. 2004;65:432–441.CrossRefGoogle Scholar
18.McElroy, SL, Zarate, CA, Cookson, J, et al.A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression. J Clin Psychiatry. 2004;65:204–210.Google Scholar
19.Calabrese, JR, Suppes, T, Bowden, CL, et al.A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry. 2000;61:841–850.CrossRefGoogle ScholarPubMed
20.Calabrese, JR, Bowden, CL, McElroy, SL, et al.Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry. 1999;156:1019–102Google Scholar
21.Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar
22.Frye, MA, Ketter, TA, Kimbrell, TA, et al.A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol. 2000;20:607–614.CrossRefGoogle ScholarPubMed
23.Bowden, CL. Valproate. In: Schatzberg, AF, Nemeroff, CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology. Washington, DC: American Psychiatric Publishing, Inc: 2004:567–579.Google Scholar
24.Judd, LL, Akiskal, HS, Schettler, PJ, et al.The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59:530–537.Google Scholar
25.Judd, LL, Akiskal, HS, Schettler, PJ, et al.A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60:261–269.Google Scholar
26.Mitchell, PB, Malhi, GS. Bipolar depression: phenomenological overview and clinical characteristics. Bipolar Disord. 2004;6:530–539.CrossRefGoogle ScholarPubMed